Download 7_Liver

Liver Proposals_Final
name: Dave Mercer
Institution: UNMC
Email:
Did you submit this proposal on behalf of an ASTS or AST committee?: Yes
If yes, please indicate which committee: LICOP- Education subcommittee
Specialty: Liver
Presentation Type: Lecture/Didactic Symposium
Proposed Session Title: Machine Perfusion Goes Prime Time in Liver Transplantation
Proposed Moderators: Jim Markmann, Harvard and Henri Leuvenink, University of Groningen
Presentation #1: Machine Perfusion to Enhance Standard Livers and Recover Otherwise Discarded
Organs
Proposed Speaker: Darius Mirza, University of Birmingham
Presentation #2: Establishing Machine Perfusion as the Standard of Care in the UK
Proposed Speaker: Peter Friend, University of Oxford
Presentation #3: Can We implement Machine Perfusion Nationally in the US?
Proposed Speaker: James Guerrera, Columbia
Goals and Objectives: Severel liver transplant units have had clinical experience of transplanting livers
using normothermic perfusion, mostly within the confines of early clinical trials. This technology has also
been shown to be effective in mitigating preservation injury and allowing liver function assessment
Liver Proposals_Final
before implantation. There may also be a role in use of this technology to make more marginal grafts
transplantable, thereby increasing the number of transplantable donor livers.
The education goals for participants include:
1) Understanding the technology of NMLP
2) Current status of clinical use of NMLP
3) Ongoing and future trials
4) Defining the role of this technology in the delivery of liver transplantation
5) health economic analysis of this technology
Name: Elizabeth Verna
Institution: Columbia University
Email: [email protected]
Did you submit this proposal on behalf of an ASTS or AST committee?: Yes
If yes, please indicate which committee: LICOP
Specialty: Infectious Disease
Kidney
Liver
Presentation Type: Controversies in Transplantation (HOT TOPIC OVERALL DEBATE CONTROVERSIES)
Liver Proposals_Final
Proposed Session Title: Using the Hepatitis C infected donor organ in the era of direct acting antivirals:
access for all or only for some?
Proposed Moderators: Elizabeth C. Verna, MD, MS, Columbia University and Peter Abt, University of
Pennsylvania
Presentation #1: HCV + grafts in solid organ transplant recipients with chronic HCV
Proposed Speaker: Norah Terrault, MPH, MD, University of California, San Francisco
Presentation #2: Pro: We should be using HCV+ Organs in All Recipients
Proposed Speaker: David Goldberg, MD, MSCE, University of Pennsylvania
Presentation #3: Con: HCV+ Organs Should Only be Used in Recipients with Active HCV
Proposed Speaker: Shirish Huprikar, MD, Icahn School of Medicine at Mount Sinai
Goals and Objectives: With the advent of direct acting anti-virals, hepatitis C has become a relatively
easily treatable infectious disease. Post-transplant treatment of hepatitis C results in high rates of
sustained virologic response with medications that are well tolerated. As the donor organ shortage
continues to worsen, the possibility of using HCV+ donors for HCV negative recipients has become a
topic of great interest. The decision to transplant a HCV+ graft is a balance between the risk of
transmission of a virus that could lead to end stage liver disease, and the benefit of access to
transplantation for a patient with a life threatening disease.
Objectives:
1.
Review the current data on the impact of a hepatitis C positive donor on graft and patient
survival after solid organ transplantation on recipients with chronic HCV.
2.
Discuss and review the impact of accepting HCV+ donors on organ access and allocation
3.
Discuss the impact of direct acting anti-viral therapy on the availability of HCV+ recipients as
well as the risk of transmission from HCV+ donors who have been previously treated
4.
Debate the utility and risk of transplanting HCV+ donor organs into patients not previously
infected with hepatitis C
Name: Walid Ayoub
Institution: Cedars Sinai Medical Center
Email: [email protected]
Liver Proposals_Final
Did you submit this proposal on behalf of an ASTS or AST committee?: Yes
If yes, please indicate which committee: AST LICOP
Specialty: Infectious Disease
Liver
Presentation Type: Lecture/Didactic Symposium – Midday Symposium
Proposed Session Title: Management of viral hepatitis before and after Solid Organ transplantation
Proposed Moderators: Walid Ayoub, MD, Cedars Sinai Medical Center and Ray Chung, MD, Mass
General
Presentation #1: Treatment of Hepatitits C Before and After Liver Transplantation
Proposed Speaker: Robert Brown, MD, New York Presbyterian Hospital
Presentation #2: Treatment of hepatitis C before and after non-liver transplantation
Proposed Speaker: Norah Terrault, MD, UCSF
Presentation #3: Management of Hepatitis B in Organ Transplant Candidates and Recipients
Proposed Speaker: Paul Martin, Univ of Miami
Goals and Objectives: -Optimize timing of treatment of hepatitis C with the new direct acting antivirals
(DAA) in patients with HCV cirrhosis before liver transplantation
-Discuss treatment of hepatitis C after liver transplantation with the direct acting antivirals.
-Discuss treatment of hepatitis B in patients with cirrhosis and after liver transplantation
-Discuss duration of HBIG therapy after liver transplantation in patients with chronic hepatitis B
Liver Proposals_Final
Name: David Foley
Institution: University of Wisconsin
Email: [email protected]
Did you submit this proposal on behalf of an ASTS or AST committee?: Yes
If yes, please indicate which committee: ASTS Grants Review Committee
Specialty: Kidney
Liver
Presentation Type: Lecture/Didactic Symposium
Proposed Session Title: Combined Liver-Kidney Transplantation: Ways to Continue Improve Outcomes
Proposed Moderators: Seth Karp, MD, Vanderbilt University and David Mulligan, MD, Yale University
Presentation #1: Overview of the New SLK Policy
Proposed Speaker: Rich Formica, Yale
Presentation #2: Delayed implantation of the kidney allograft
Liver Proposals_Final
Proposed Speaker: Burcin Ekser, Indiana
Presentation #3: Appropriate Monitoring of the Kidney Graft in SLK
Proposed Speaker: Lorenzo Gallon, Northwestern
Goals and Objectives: To identify strategies aimed at improving outcomes in patients undergoing
combined liver and kidney transplantation. After this session attendees will be able to learn new
strategies that can be implemented at their own institutions. Topics will focus on the timing of CLK,
utilization of high KDPI kidneys and the role of desensitization in these challenging recipients.
Name: Maria Doyle
Institution: Washington University School of Medicine
Liver Proposals_Final
Email: [email protected]
Did you submit this proposal on behalf of an ASTS or AST committee?: No/AST LICOP Education
Subcommittee and LICOP Executive Committee
If yes, please indicate which committee:
Specialty: Liver
Presentation Type: Lecture/Didactic Symposium - Midday
Proposed Session Title: Liver Transplant for HCC in the Next Decade
Proposed Moderators: Christopher Sonnenday, University of Michigan and Goren Klintmalm, Baylor,
Dallas, TX
Presentation #1: Evolution of Liver Transplant for HCC: 20 Years Post-Milan
Proposed Speaker: Vincenzo Mazzafero, MD, INstituto Nazional Tumor, Milan Italy
Presentation #2: Evolution of UNOS Policies for HCC: What does the Future Hold?
Proposed Speaker: Ryu Hirose, UCSF
Presentation #3: HCC and NASH: The sleeping giant and the potential future
Proposed Speaker: Steve Harrison, San Antonio, TX
Goals and Objectives:
N
Liver Proposals_Final
Name: Amit Mathur
Institution: Mayo Clinic Arizona
Email: [email protected]
Did you submit this proposal on behalf of an ASTS or AST committee?: Yes
If yes, please indicate which committee: Living Donor
Specialty: Liver
Presentation Type: Lecture/Didactic Symposium- Sunrise
Proposed Session Title: DCD Liver Transplantation: Current Controversies and Future Directions
Proposed Moderators: Linda Sher, MD, University of Southern California and Amit Mathur, Mayo Clinic
Arizona
Presentation #1 : Best Practices in the Use of Deceased After Cardiac Death Hepatic Allografts
Proposed Speaker: George Loss, MD, Ochsner Medical Center
Presentation #2 : Future Directions in DCD Liver Transplantation: Is the Pump the Solution?
Proposed Speaker: Peter Friend, Univeristy of Cambridge
Liver Proposals_Final
Presentation #3: New Basic and Translational Science in Protecting DCD Allografts
Proposed Speaker: David Foley, MD, Wisconsin
Goals and Objectives: - Frame the current state of DCD liver transplantation in the US and beyond by
reviewing single center and registry data
- Review limitations of broader utilization of DCD livers
- Review controversies in the world of DCD liver transplantation surrounding donor selection and
surgical practices
- Discuss human experience with warm pump technology for DCD liver transplantation
Name: Georgios Tsoulfas
Institution: Aristotle University of Thessaloniki, Thessaloniki, Greece
Email: [email protected]
Did you submit this proposal on behalf of an ASTS or AST committee?: Yes
If yes, please indicate which committee: AST LICOP
Specialty: Liver
Liver Proposals_Final
Presentation Type: Lecture/Didactic Symposium
Proposed Session Title: Expanding the liver donor pool: the art of allocation
Proposed Moderators: Benedict AB Cosimi, MD, MGH, Harvard University and Georgios Tsoulfas, MD,
PhD, Aristotle University of Thessaloniki, Thessaloniki, Greece
Presentation #1: What is really an extended criteria donor? Are all extended criteria grafts created
equal?
Proposed Speaker: Peter Abt, MD, University of Pennsylvania
Presentation #2: The challenges involved in allocating extended criteria donors
Proposed Speaker: Adel Bozorgzadeh, MD, University of Massachusetts
Presentation #3: Planning a strategy for optimal use of extended criteria donors based on the last 15
years of experience
Proposed Speaker: Joseph Tector, MD, University of Alabama
Goals and Objectives: 1. To discuss the challenge of finding common ground on what constitutes an
extended criteria donor – or alternatively point out the reasons for the significant variations seen.
2.
To discuss different practices in allocating extended criteria donors and lessons learnt.
3.
To discuss the ways that extended criteria donors (or at least certain subgroups among them)
can be actively used to increase the availability of grafts.
Liver Proposals_Final
Name: Thomas Schiano
Institution: Icahn School of Medicine at Mount Sinai
Email: [email protected]
Did you submit this proposal on behalf of an ASTS or AST committee?: No
If yes, please indicate which committee:
Specialty: Liver
Presentation Type: Luncheon Workshop
Proposed Session Title: Liver Transplant Histopathology and Clinical Correlation: A Review of Both the
Basic and Complex
Proposed Moderators:
Presentation #1: Case Series 1: The Donor Liver Biopsy
Proposed Speaker: Thomas D. Schiano, MD, FAST, Icahn School of Medicine at Mount Sinai
Presentation #2: Case Series 2: The Recipient Liver Biopsy
Proposed Speaker: M. Isabel Fiel, M.D., Icahn School of Medicine at Mount Sinai
Goals and Objectives: Fewer liver biopsies are being performed in light of the availability of new
medications for hepatitis C that are improving patient outcomes and are thus obviating the need for
protocol liver biopsies and the need to know the degree of liver fibrosis. Thus when a biopsy is
Liver Proposals_Final
performed liver biopsy interpretation is typically more challenging for the clinician and pathologist alike.
Histological donor biopsy assessment is critical in deciding upon donor:recipient matching, and there is
increasing awareness of antibody-mediated rejection in liver transplantation which has quite complex
histological findings. Both of these will be discussed, as well as a concise review of other typical postliver transplant histopathological findings such as the recurrence of viral hepatitis and other diseases, as
well as biliary and vascular complications. As rejection rates have decreased over the years, clinicians
are less familiar with the histological features of acute cellular and chronic ductopenic rejection so this
will also be reviewed. Lectures will be given by liver pathologists experienced in liver transplant
pathology, with the moderators able to give both a clinician's perspective and pathological viewpoint
and feedback to the talks. There is a dearth of lectures involving pathology at ATC and such a
symposium will be attractive to clinicians, fellows and pathologists alike.
Name: Kyung-Suk Suh
Institution: Seoul National University Hospital
Email: [email protected]
Did you submit this proposal on behalf of an ASTS or AST committee?: No
If yes, please indicate which committee:
Specialty: Liver
Presentation Type: Lecture/Didactic Symposium- Sunrise Interactive Video Session
Proposed Session Title: Advances of laparoscopic technique in living donor hepatectomy
Proposed Moderators: Kyung-Suk Suh, M.D., Seoul National University Hospital and Kim Olthoff, UPEN
Presentation #1: Pure Laparoscopic donor right hepatectomy using ICG technique
Proposed Speaker: Kyung-Suk Suh, Seoul National University Hospital
Presentation #2: Hybrid and other modified laparoscopic donor hepectomy
Proposed Speaker: Olivier Soubrane, Beacon Hospital France
Liver Proposals_Final
Presentation #3: Robot-assisted Donor Hepatectomy
Proposed Speaker: Pier Giulianotti, University of Illinois at Chicago, Chicago, IL
Goals and Objectives: learn new technique of laparoscopic donor hepatectomy
learn usefulness of Indocyanine green test for the segmentation and bile duct anatomy
learn future surgery using Robot system
Name: Helen Te
Institution: Univ of Chicago Medicine
Email: [email protected]
Did you submit this proposal on behalf of an ASTS or AST committee?: Yes
If yes, please indicate which committee: LICOP
Specialty: Liver
Presentation Type: Lecture/Didactic Symposium - Sunrise
Liver Proposals_Final
Proposed Session Title: Fine-tuning Immunosuppression in Liver Transplantation
Proposed Moderators: Helen S. Te, MD, Univ of Chicago and Thomas Schiano, MD, Mount Sinai of New
York
Presentation #1: 1. Rejection in 2017: “Big” or “Little” Deal in Liver Recipients
Proposed Speaker: Josh Levistky, MD, Northwestern
Presentation #2: Complete immunosuppression withdrawal in children and adults – how close are we?
Proposed Speaker: Sandy Feng, MD, UCSF
Presentation #3: Personalized immunosuppression– is it ready for prime time and if not, when?
Proposed Speaker: Avi Shaked, Penn
Goals and Objectives: 1.To discuss viable strategies to treatment of steroid-resistant acute rejection of
the liver graft.
2.
To discuss current data from immunosuppression withdrawal trials and markers that may
predict success of withdrawals.
3.
To examine the utility of various measures of immunosuppression beyond serum drug levels in
clinical practice.
Name: Seth Karp
Institution: Vanderbilt
Email: [email protected]
Did you submit this proposal on behalf of an ASTS or AST committee?: No
If yes, please indicate which committee:
Specialty: Liver
Liver Proposals_Final
Presentation Type: Lecture/Didactic Symposium
Proposed Session Title: Alternatives to liver redistricting to improve fairness in liver allocation
Proposed Moderators: Richard Gilroy, Intermountain and Julie Heimbach, Mayo Rochester
Presentation #1: Alternative models for liver allocation using nearest neighbor algorithms
Proposed Speaker: Sanjay Mehotra, Northwestern
Presentation #2: Burden of liver disease as a measure of disparity in liver allocation
Proposed Speaker: David Goldberg, U Penn
Presentation #3: Determining the true potential of organ donation in a community as a way to decrease
disparity in liver allocation
Proposed Speaker: Richard Hasz, Gift of Life
Goals and Objectives: This session will present alternatives to redistricting that may be superior to
current proposals. The objective will be to help the community understand other solutions to the
disparity problem
Liver Proposals_Final
Name: Lisa VanWagner
Institution: Northwestern University
Email: [email protected]
Did you submit this proposal on behalf of an ASTS or AST committee?: Yes
If yes, please indicate which committee: LICOP
Specialty: Liver
Presentation Type: Lecture/Didactic Symposium - Sunrise
Proposed Session Title: Cardiac Function in Liver Transplantation: Assessing and Mitigating Risk Across
the Continuum of Care
Proposed Moderators: Laura Hammel, Wisconsing and Lisa VanWagner, MD, MSc, Northwestern
University
Presentation #1: Evaluation and management of cardiac disease in liver transplant candidates
Proposed Speaker: Amit Patel, MD, Univ of Chicago
Presentation #2: Management of Cardiac Dysfunction after Liver Transplantation
Proposed Speaker: James Mudd, MD, Oregon Health and Science University
Case Based Discussion: Discuss by panel 3-4 cases of complicated cardiac disease in LT (CAD, valve
disease, cirrhotic cardiomyopathy, etc)- Organize/Led by Lisa Van Wagner
Goals and Objectives: At the end of this session, participants will be able to:
Define risk factors and select appropriate evaluation strategies for non-ischemic cardiac
conditions in liver transplant candidates
Liver Proposals_Final
Describe management strategies for non-ischemic cardiac conditions in the liver transplant
candidate
-
Explain the liver-related complications that arise in patients with congenital cardiac defects
-
Evaluate a patient with congenital heart disease for liver transplantation
-
Define cirrhotic cardiomyopathy and its associated pathophysiology
Describe the management approach for cirrhotic cardiomyopathy pre- and post-liver
transplantation
Name: Georgios Tsoulfas
Institution: Aristotle University of Thessaloniki, Thessaloniki, Greece
Email: [email protected]
Did you submit this proposal on behalf of an ASTS or AST committee?: Yes
If yes, please indicate which committee: AST LICOP
Specialty: Liver
Psychosocial and Ethics
Presentation Type: Lecture/Didactic Symposium – Sunrise Symposium
Proposed Session Title: Alcohol and Liver Transplantation: Is it time for a reality check?
Proposed Moderators: Raymond Chung, MD, MGH, Harvard University and Georgios Tsoulfas, MD, PhD,
FACS, Aristotle University of Thessaloniki, Greece
Presentation #1: Alcoholic liver disease and liver transplantation: what are the challenges involved?
Proposed Speaker: Thomas Schiano, Ichan School of Medicine, Mt. Sinai
Presentation #2: The ethics of liver transplantation in the management of alcoholic liver disease
Liver Proposals_Final
Proposed Speaker: Katrina A. Bramstedt, PhD, Professor, Transplant Ethicist, Bond University,
Queensland, Australia
Presentation #3: Can we predict recidivism after liver transplantation and does it really matter?
Proposed Speaker: Andrea DiMartini, PharmD, University of Pittsburgh
Goals and Objectives: 1. To discuss the full spectrum of alcoholic liver disease, and the role of liver
transplantation as part of a multimodal treatment strategy with special emphasis on outcomes for liver
transplantation for alcoholic liver disease compared to other etiologies.
2.
To discuss the incidence and effect of recidivism after liver transplantation for alcoholic liver
disease.
3.
To discuss the ethical dilemmas presented to the medical and surgical team by the existing
abstinence listing criteria, especially in the case of acute on chronic liver failure secondary to alcoholic
liver disease.
Name: Adnan Said
Institution: University of Wisconsin School of Medicine and Public Health
Email: [email protected]
Did you submit this proposal on behalf of an ASTS or AST committee?: Yes
If yes, please indicate which committee: LICOP- Education subcommittee
Specialty: Liver
Small Bowel
Presentation Type: Lecture/Didactic Symposium – Midday
Proposed Session Title: Keeping the high MELD/PELD patient alive on the list
Proposed Moderators: Adnan Said, University of Wisconsin School of Medicine and Public Health,
Madison and Janice Jou, Oregon Health Sciences University
Liver Proposals_Final
Presentation #1: New strategies for the management of acute on chronic liver failure
Proposed Speaker: Rajiv Jalan, University College London, Royal Free Hospital, UK
Presentation #2: Infection in the Wait-Listed Liver Transplant Candidate
Proposed Speaker: Andre Kalil, UNMC
Presentation #3: Too sick for transplant: Frailty, Nutrition and Predictive Score Assessments
Proposed Speaker: Jennifer Lai, University of California San Francisco
Goals and Objectives: Presentation 1
Patients with cirrhosis can present with acute on chronic liver failure (ACLF) a distinct entity with high
short-term mortality (over 30% at 28 days). This prevalent and devastating complication of cirrhosis
requires hospitalization and frequently intensive care
The goals of this talk are:
•
Recognition of ACLF as proposed by validated guidelines in the literature (EASL-CLIF)
•
Effective multidisciplinary approach to management of ACLF (intensive care physicians,
hepatologists, nutritionists, infectious disease specialists and other)
.
•
Strategies and evolving therapies for management of ACLF including for SIRS/Sepsis, Acute
Kidney Injury, Hepatic encephalopathy, coagulation/bleeding disorders and circulatory/vasopressor
support. The role of extracorporeal liver support if applicable, and data to support use of these
therapies in patients on the liver transplant waiting list
Presentation 2
Malnutrition is common and multifactorial in patients with cirrhosis (decreased intake, catabolism,
inflammation, decreased gut function) and linked to morbidity/mortality both on the waiting list and
post transplant
•
This talk will discuss the evidence and guidelines for nutritional support for patients with
cirrhosis on the waiting list.
•
What are the recommendations for enteral and parenteral support in these patients?
•
What is optimal energy intake, protein intake, role of micronutrients, including vitamins and
minerals
•
What is the evidence that nutritional support impacts patient outcomes on the waiting list
Liver Proposals_Final
Presentation 3
Patients on the waiting list suffer not only from complications of liver disease, but also physical frailty
and sarcopenia and extrahepatic comorbidities. The combined effect of these multiple hits leads to
decreased quality of life, increased resource utilization, morbidity and mortality and poor post
transplant outcomes.
•
What are validated assessments of frailty that can be used in these patients.
•
What are the roles of these assessments in longitudinal evaluation of patients on the waiting list
and in making the decision to transplant versus delist a patient